Five things to know about: Mixing and matching coronavirus vaccines

Amid global vaccine rollouts, with nearly 1.2 billion doses currently administered, some countries have recommended a mixed-dose approach where a first prime shot is followed by a booster of a second type.  The measure has been introduced by France and Germany for people who received a first dose of the AstraZeneca vaccine but are in age groups for which that vaccine is … Read more

Q&A: Nanobots could explore human cells – but their size is an engineering challenge

Scientists are developing virus-sized robots that could defuse blood clots, explore human cells or even scrub water of impurities. But as these inventions get smaller, the laws of motion that govern these machines are not very intuitive, so researchers are drawing inspiration from nature, says Brad Nelson, professor of robotics at ETH Zürich, Switzerland, who … Read more

Q&A: BioNTech vaccine is only ‘mRNA 1.0’. This is just the beginning, say co-founders

The successful development of mRNA vaccines for Covid-19 is ‘transformational’ and opens the doors to new types of vaccines for other infectious diseases as well as cancer, according to Dr Özlem Türeci and Dr Uğur Şahin, the co-founders of Germany’s BioNTech. The main question, they say, is which vaccine to prioritise first. The Pfizer/BioNTech coronavirus vaccine was … Read more

How a year of coronavirus activity unfolded at the EU’s medicines regulator

The speed with which coronavirus vaccines have been developed surprised everyone and could transform public health into the future, says Dr Fergus Sweeney, head of the clinical studies and manufacturing taskforce at the European Medicines Agency (EMA). Here he gives us a glimpse at the work of the regulator over the past year as part … Read more